The Longitudinal Course of Psychopathology in Cushing’s Syndrome after Correction of Hypercortisolism
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Endogenous Cushing’s syndrome (CS) is associated with significant psychopathology during the course of the disease. The purpose of this study was to evaluate the psychological and endocrine status of patients with CS after correction of their hypercortisolism. Thirty-three patients with active CS were examined before and at 3 months (28 patients), 6 months (25 patients), and 12 months (29 patients) after correction of hypercortisolism. Before cure, 66.7% of the patients had significant psychopathology, with the predominant diagnosis of atypical depressive disorder (AD) in 51.5% and/or major affective disorder in 12%. After cure, overall psychopathology decreased significantly to 53.6% at 3 months, 36% at 6 months, and 24.1% at 12 months, when there was a parallel recovery of the hypothalamic-pituitary-adrenal axis assessed by serial morning ACTH stimulation tests. There was an inverse correlation between psychological recovery and baseline morning cortisol, but no correlation with ACTH-stimulated cortisol values at 60 min. AD continued to be the prevailing diagnosis after correction of hypercortisolism, whereas the frequency of suicidal ideation and panic increased. The presence of AD before and after correction of hypercortisolism might be due to glucocorticoid-induced suppression of hypothalamic CRH secretion. The slight increase in the incidence of panic after correction of hypercortisolism might be due to a decreased glucocorticoid restraint at the central arousal/sympathetic catecholaminergic system. We conclude that CS is associated with AD symptomatology, which gradually improves with time after correction of hypercortisolism. Health care providers should be aware of changes in symptomatology, including suicidal ideation and panic attacks, that occur in a subgroup of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GWS occurs due to a relative decrease in cortisol concentrations after surgical cure, and consists not only of physical signs and symptoms, but also psychiatric symptoms (such as depression and anxiety), which affect recovery and overall quality of life24,25.”
From Extensive clinical experience: hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess (2018) · cites this paper as [24]
Citations
Cites
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · cited 1×
“Interrater agreement on the presence or absence of a psychiatric diagnosis was made on approximately 32% of the posttreatment interviews throughout the course of the study. The average k coefficient ( 22 ) was 0.87.”
BackgroundInfluential(1970) · Cited by 24,983
The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis
Chrousos, G. P. (1992) · JAMA · doi:10.1001/jama.1992.03480090092034 · Cited by 2,689 · cited 3×
“In an earlier report we showed that over 50% of patients with active CS present with symptoms of atypical depression (6), a phenomenon compatible with the fact that patients with active CS exhibit glucocorticoid-induced suppression of their CRH neurons ( 9 , 10, 17).”
BackgroundResultInfluentialSelf-citationWilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115 · cited 1×
“The Hamilton Rating Scale for Depression ( 24 ) consists of 21 items and yields scores of depression severity from 0‐65.”
MethodDEMITRACK, M. A., DALE, J. K., STRAUS, S. E., LAUE, L., LISTWAK, S. J., KRUESI, M. J. P., CHROUSOS, G. P., & GOLD, P. W. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1224 · Cited by 727 · cited 1×
“To date, the coexistence of atypical depression and low hypothalamic CRH secretion has been shown or inferred in patients with active CS (10), seasonal affective disorder (11), the chronic fatigue/fibromyalgia syndromes ( 12 , 13), and the postpartum blues/depression syndromes (14).”
BackgroundSelf-citationHypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia
Crofford, L. J., Pillemer, S. R., Kalogeras, K. T., Cash, J. M., Michelson, D., Kling, M. A., Sternberg, E. M., Gold, P. W., Chrousos, G. P., & Wilder, R. L. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371105 · Cited by 508 · cited 1×
“To date, the coexistence of atypical depression and low hypothalamic CRH secretion has been shown or inferred in patients with active CS (10), seasonal affective disorder (11), the chronic fatigue/fibromyalgia syndromes (12, 13 ), and the postpartum blues/depression syndromes (14).”
BackgroundSelf-citationKendler, K. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050025004 · Cited by 323
Risk factors and long-term outcome in pituitary-dependent Cushing's disease
Sonino, N. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2647 · Cited by 265 · cited 1×
“Others reported that postoperative depression was a predictor of both nonremission and relapse after pituitary surgery of Cushing’s disease ( 33 ).”
BackgroundPhenelzine v Imipramine in Atypical Depression: A Preliminary Report
Liebowitz, M. R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790180039005 · Cited by 261
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.1.52 · Cited by 247
Research works printed but not linked: 4
- Gifford, 1970, 49, 397
- Kelly, 1983, 142, 16
- Munabi, 1986, 63, 1036
- Endicott, 1979, 136, 52
Cited by
Items 101–200 of 264
Mental Fatigue and Executive Dysfunction in Patients with Cushing’s Syndrome in Remission
Papakokkinou, E., Johansson, B., Berglund, P., & Ragnarsson, O. (2015) · Behavioural Neurology · doi:10.1155/2015/173653 · Cited by 29
“Mood disorders and cognitive impairment occur in 50– 80% of patients with active CD [2].”
BackgroundTreatment of severe psychosis due to ectopic Cushing’s syndrome
Bilgin, Y. M., van der Wiel, H. E., Fischer, H. R. A., & de Herder, W. W. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03350817 · Cited by 35
Oßwald, A., Deutschbein, T., Berr, C., Plomer, E., Mickisch, A., Ritzel, K., Schopohl, J., Beuschlein, F., Faßnacht, M., Hahner, S., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0212 · Cited by 35
Atypical depression spectrum disorder – neurobiology and treatment
Murck, H. (2003) · Acta Neuropsychiatrica · doi:10.1034/j.1601-5215.2003.00029.x · Cited by 37
“Some authors stress the similarity between AD and Cushing’s disease, as in the latter about 50% of patients meet the diagnostic criteria of AD (143) and the symptoms improve after treatment (144).”
BackgroundQuality of Life in Cushing's disease: A long term issue?
Webb, S. M., Vives, A. S., Resmini, E., Martínez-Momblán, M.-A., Martel‐Duguech, L., & Valassi, E. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.007 · Cited by 38
Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Lewis, G. F., Leiter, L. A., MacQueen, G. M., Miranda, A., Fulgosi, D., Konarski, J. Z., & Kennedy, S. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1615 · Cited by 32
“For example, patients with Cushing’s syndrome, characterized by chronic elevation of endogenous cortisol levels, have cognitive impairment and a high incidence of depression which resolves with correction of the hypercortisolemia [97,98] .”
BackgroundBengtsson, D., Ragnarsson, Ó., Berinder, K., Dahlqvist, P. M., Engström, B. E., Ekman, B., Höybye, C., Burman, P., & Wahlberg, J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab079 · Cited by 34
“In accordance with previous prospective studies (7-9,15,27), some patients seemed to improve; however, at 5-year follow-up, 66% of the patients who were on treatment with antidepressant drugs at diagnosis had continued therapy, and 16 of 129 (12%) had started antidepressant therapy after diagnosis.”
BackgroundResultInfluentialMilian, M., Honegger, J. B., Gerlach, C., & Psaras, T. (2013) · Acta Neurochirurgica · doi:10.1007/s00701-013-1809-7 · Cited by 32
“and remain stable during the further course [7].”
Mifepristone: is there a place in the treatment of Cushing’s disease?
Carmichael, J. D., & Fleseriu, M. (2012) · Endocrine · doi:10.1007/s12020-012-9846-1 · Cited by 33
Beyond fast food and slow motion: weighty contributors to the obesity epidemic.
Cizza, G., & Rother, K. I. (2012) · PubMed · doi:10.3275/8182 · Cited by 26
“Approximately 2/3 of patients with hypercortisolemia secondary to endogenous Cushing’s syndrome have psychopathological symptoms, mostly atypical depression which tends to gradually disappear 312 months after surgical cure, as plasma cortisol levels normalize (78).”
Resmini, E., Vives, A. S., & Webb, S. M. (2016) · Frontiers of hormone research · doi:10.1159/000443868 · Cited by 36
Psaras, T., Milian, M., Hattermann, V., Will, B. E., Tatagiba, M. S., & Honegger, J. B. (2011) · PubMed · doi:10.3275/7333 · Cited by 31
Webb, S. M., Ware, J. E., Forsythe, A., Yang, M., Badia, X. C., Nelson, L. M., Signorovitch, J., McLeod, L., Maldonado, M., Zgliczyński, W., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-1013 · Cited by 29
Khiat, A., Bard, C., Lacroix, A., & Boulanger, Y. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02147-8 · Cited by 36
Vogel, F., Braun, L., Zopp, S., Nowak, E., Schreiner, J., Benz, I., Rubinstein, G., Künzel, H., Ritzel, K., Kroiss, M., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad041 · Cited by 28
Neuropsychiatric disorders and cognitive dysfunction in patients with Cushing's disease
Chen, Y., Li, Y., Xiao, C. H. E. N., & Sun, Q. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20130944 · Cited by 31
“Cerebral atrophy has been shown to be partially reversible in patients with CD.42 So, by discovering these neuropsychiatric disorders and cognitive dysfunction in patients with CD and offering therapeutic strategy early are very important for improving QoL for patients with CD.”
BackgroundInfluentialDiagnosis and treatment of pediatric Cushing’s disease
Savage, M. O., Storr, H. L., Chan, L. F., & Grossman, A. B. (2007) · Pituitary · doi:10.1007/s11102-007-0056-4 · Cited by 26
“Studies of adult patients with CS have reported brain atrophy, cognitive impairment, and psychopathology, most commonly depression, associated with excess endogenous circulating glucocorticoids [48].”
BackgroundMilian, M., Honegger, J. B., Teufel, P., Wolf, A., & Psaras, T. (2013) · Neuroendocrinology · doi:10.1159/000355622 · Cited by 25
Cases of Psychiatric Morbidity in Pediatric Patients After Remission of Cushing Syndrome
Keil, M. F., Zametkin, A. J., Ryder, C., Lodish, M. B., & Stratakis, C. A. (2016) · PEDIATRICS · doi:10.1542/peds.2015-2234 · Cited by 24
Biological Markers of Atypical Depression
Posternak, M. A. (2003) · Harvard Review of Psychiatry · doi:10.1080/10673220303941 · Cited by 28
A direct comparison of quality of life in obese and Cushing's syndrome patients
Abraham, S. B., Abel, B. S., Rubino, D., Nansel, T. R., Ramsey, S., & Nieman, L. K. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-1078 · Cited by 25
Psychiatric aspects of endocrine disorders in women
Joffe, R. T., Brasch, J. S., & MacQUEEN, G. M. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00033-9 · Cited by 24
“As with other endocrine syndromes, specific treatment of the Cushing’s syndrome generally leads to improvement in psychiatric symptoms [13,14].”
BackgroundThe physiology of stress and the human body’s response to stress
Lee, R. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823039-8.00017-4 · Cited by 28
Are patients with pituitary adenomas at an increased risk of mental disorders?
Korali, Z., Wïttchen, H., Pfister, H., Höfler, M., Oefelein, W., & Stalla, G. K. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.02383.x · Cited by 22
Lack of functional remission in Cushing’s syndrome
Vermalle, M., Alessandrini, M., Graillon, T., Paladino, N. C., Baumstarck, K., Sebag, F. A., Dufour, H., Brue, T. C., & Castinetti, F. (2018) · Endocrine · doi:10.1007/s12020-018-1664-7 · Cited by 22
Translating depression biomarkers for improved targeted therapies
Bredt, D. S., Furey, M. L., Chen, G., Lovenberg, T., Drevets, W. C., & Manji, H. K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.013 · Cited by 23
Severe hypertension and hypokalemia as first clinical manifestations in ectopic Cushing's syndrome
Fernández-Rodríguez, E., Villar‐Taibo, R., Pinal-Osorio, I., Cabezas-Agrícola, J. M., Anido, U., Prieto, A., Casanueva, F. F., & Araújo‐Vilar, D. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000600019 · Cited by 20
Pronóstico del paciente tratado de síndrome de Cushing
Aulinas, A., Valassi, E., & Webb, S. M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.03.008 · Cited by 21
Residual symptoms in depression
Sonino, N., & Fava, G. A. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00200-2 · Cited by 23
Heuser, I. (2001) · Springer eBooks · doi:10.1007/978-3-642-59519-6_8 · Cited by 18
Cushing Disease Presenting as Primary Psychiatric Illness: A Case Report and Literature Review
Rasmussen, S. A., Rosebush, P. I., Smyth, H. S., & Mazurek, M. F. (2015) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000113 · Cited by 21
Ciarlone, S. L., Statz, J. K., Goodrich, J. A., Norris, J. N., Goforth, C. W., Ahlers, S. T., & Tschiffely, A. E. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24604 · Cited by 16
“…in improvements in neuropsychiatric symptoms, chronic dysfunction may lead to delayed recovery or persistent neuropsychological impairment; therefore, it is imperative to monitor, identify, and address these neuroendocrine alterations as early as possible (Dorn et al., 1997; van Aken et al., 2005).”
BackgroundRole of adrenalectomy in recurrent Cushing's disease
Ding, X., Li, H., Yan, W., Gao, Y., & Li, X. (2010) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.2010.13.008 · Cited by 16
Characterization of persistent and recurrent Cushing’s disease
Sundaram, N. K., Carluccio, A. L., & Geer, E. B. (2013) · Pituitary · doi:10.1007/s11102-013-0511-3 · Cited by 19
“In addition, sustained neuropsychiatric abnormalities such as impairments of memory and language performance, as well as persistence of depression, anxiety, and mania is well documented in patients after resolution of hypercortisolism [84–87].”
BackgroundStress-axis, coping and dementia: gene-manipulation studies
Heinrichs, S. C. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01335-8 · Cited by 19
Stachowska, B., Kuliczkowska-Płaksej, J., Kałużny, M., Grzegrzółka, J., Jończyk, M., & Bolanowski, M. (2020) · Endocrine · doi:10.1007/s12020-020-02468-1 · Cited by 15
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome
Geer, E. B., Grillo, I., Li, Q., Robins, H., Cohen, V. V., Baratz, H. Q., Garcia, C., Sazo, M., Lin, A. L., Cohen, M. A., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01450-8 · Cited by 15
“Given the known associations between insomnia, neurocognitive impairment, and metabolic dysregulation, sleep disturbance over time may worsen the neuropsychological and body composition abnormalities that are well documented in treated CS patients [12, 19–23].”
BackgroundPsychiatric Manifestations of Endocrine Disorders
Solomon, S. S. (2017) · Human Endocrinology · doi:10.24966/he-9640/100007 · Cited by 17
Neuropsychological and Emotional Functioning in Patients with Cushing’s Syndrome
Na, S. D., Fernandes, M. A., Ioachimescu, A. G., & Penna, S. (2020) · Behavioural Neurology · doi:10.1155/2020/4064370 · Cited by 16
Durcan, E., Turan, Ş., Şahin, S., Sulu, C., Taze, S. S., Kavla, Y., Özkaya, H. M., & Kadıoğlu, P. (2021) · Pituitary · doi:10.1007/s11102-021-01136-5 · Cited by 16
“1% of the patients in the third month of their treatment, but that anxiety regressed in all patients after 6 to 12 months [34].”
BackgroundPhysiology and Pathophysiology of the HPA Axis
de Castro, M., Elias, L. L. K., Elias, P. C. L., & Moreira, A. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_1 · Cited by 19
Introduction to Epigenetics in Psychiatry
Lee, R. S., & Avramopoulos, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417114-5.00001-2 · Cited by 16
Baba, M., & Ray, D. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0571-0 · Cited by 14
“The majority of patients will improve in the first few weeks [14,15]; however, 36% of patients will still be symptomatic after 12 months [15].”
BackgroundThe human hypothalamus in metabolic and episodic disorders
Swaab, D. F. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)53001-8 · Cited by 17
Mullan, K., & Atkinson, A. B. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03028.x · Cited by 15
Improving Quality of Life in Patients with Pituitary Tumours
Crespo, I., Vives, A. S., Resmini, E., Valassix, E., Martínez-Momblán, M.-A., & Webb, S. M. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.01.32 · Cited by 13
Milian, M., Honegger, J. B., Gerlach, C., Hemeling, X., & Psaras, T. (2014) · Neuroendocrinology · doi:10.1159/000364878 · Cited by 16
Tirosh, A., RaviPrakash, H., Papadakis, G. Z., Tatsi, C., Belyavskaya, E., Lyssikatos, C., Lodish, M. B., Bağcı, U., & Stratakis, C. A. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz303 · Cited by 12
Psychiatric Manifestations of Cushing’s Syndrome
Loosen, P. T. (2002) · Springer eBooks · doi:10.1007/978-1-4615-1103-8_3 · Cited by 12
Coping with Cushing’s Disease: the Patients’ Perspectives
Vives, A. S., & Webb, S. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00010-3 · Cited by 11
Theodorou, A., Tan, E. C., Bakkar, M. A., Reiner, A. S., Sazo, M., Cohen, M. A., Lin, A. L., Tabar, V. S., & Geer, E. B. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf598 · Cited by 10
Hypothalamo-Pituitary-Adrenal Axis in Depressive Disorders and Treatment Resistance
Yunilaynen, O. A., Starostina, E. G., & Oleichik, I. V. (2023) · Psikhiatriya · doi:10.30629/2618-6667-2023-21-1-73-90 · Cited by 10
Cognitive decline in Cushing's syndrome: A systematic review
Katragadda, A., Kunadia, J., Kirsch, P. M., Dorcely, B., Shah, S., Henig, Z., Job, A., Feelders, R. A., & Agrawal, N. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13466 · Cited by 12
Prognosis of patients treated for Cushing syndrome
Aulinas, A., Valassi, E., & Webb, S. M. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.01.004 · Cited by 13
Matching the Diameter of ePTFE Bypass Prosthesis with a Native Artery Improves Neoendothelialization
Çıkırıkçıoğlu, M., Pektok, E., Cikirikcioglu, Y. B., Lujan, S. M. O., Tille, J., Kalangos, A., & Walpoth, B. H. (2008) · European Surgical Research · doi:10.1159/000118029 · Cited by 10
Who and how to screen for endogenous hypercortisolism in patients with mood disorders
Ferrante, E., Simeoli, C., Mantovani, G., & Pivonello, R. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02457-5 · Cited by 10
“Similarly, anxiety disorders may improve after CS remission; indeed, a study described that 6 months after CS treatment, consisting in surgery, irradiation or medical therapy, no patients presented with anxiety disorders [19].”
Walia, R., Kumar, N., Jarial, K. D. S., Bhansali, A. K., Nehra, R., & Vyas, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_162_20 · Cited by 9
“[1‑4] The first description of neuropsychiatric disturbances was described by Harvey Cushing’s in 1932 in his original description in a series of 12 patients of CS and highlighted the presence of emotional disturbances as a pathologic feature of CS.[5] Various neuropsychiatric disorders like major depression, mania, a…”
BackgroundInfluentialAntonoudiou, P., Stone, B. T., Colmers, P. L. W., Evans‐Strong, A., Walton, N. L., & Maguire, J. L. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13274 · Cited by 10
Sawant, N., Sharma, A., & Shah, N. S. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_94_18 · Cited by 10
“The prevalence rates for depression have been documented as 54%,[26] 67%,[27] and 74%[28] in patients of CD.”
BackgroundAssociation of Cortisol Levels With Neuropsychiatric Functions: A Mendelian Randomization Analysis
Zhou, X., & Qiao, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00564 · Cited by 9
“Findings from observational studies further show that recovery of hypercortisolemia is associated with recovery of depression (1, 28).”
BackgroundAre there Reliable Predictors for the Impaired Quality of Life in Patients With Cushing’s Syndrome?
Nankova, A., Yaneva, M., Elenkova, A., Kalinov, K., & Zacharieva, S. (2019) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2019.482 · Cited by 9
“The persistent changes in the physical and mental state of patients with CS after cure of the disease might explain not fully recovery of the QoL (27, 28).”
BackgroundCortisol, depression and reduced cortico-cortical cross-talk in Cushing’s syndrome
Schutter, D. J. L. G., van Honk, J., de Haan, E. H. F., van Huffelen, A. C., & Koppeschaar, H. P. F. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347504 · Cited by 10
“(26) have demonstrated that depressive symptomatology can persevere up to a year after correction of hypercortisolism, hence indicative for a complex dissociation between cortisol and depression, more systematically controlled and longitudinal studies are required to scrutinize the here-observed relationships.”
BackgroundBlevins, L. S. (2013) · Wiley eBooks · doi:10.1002/9781118559406.ch8 · Cited by 9
How to manage Cushing's disease after failed primary pituitary surgery
Agrawal, N., Urwyler, S. A., Mehta, S., Karavitaki, N., & Feelders, R. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae110 · Cited by 8
Manic Episodes Due to Medical Illnesses: A Literature Review
Torales, J. C., González, I., Barrios, I., Ventriglio, A., & Bhugra, D. (2018) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000875 · Cited by 8
Persistent Comorbidities in Cushing’s Syndrome after Endocrine Cure
Resmini, E. (2014) · Advances in Endocrinology · doi:10.1155/2014/231432 · Cited by 9
“Subtle cognitive defects [128] and impaired quality of life [130] are common in cured CS and psychopathology is reported in 25% of the patients after endocrine control [114, 115].”
BackgroundGold, P. W., & Wong, M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03019-8 · Cited by 7
Self-citationFernandes, M. A., Hickle, S. D., Penna, S., Ioachimescu, A. G., & Tone, E. B. (2024) · Behavioural Neurology · doi:10.1155/2024/4393169 · Cited by 8
“[6], as well as neurocognitive impairments in memory and concentration [7, 8].”
In what clinical settings should Cushing's syndrome be suspected?
Bruno, O. D., Juárez‐Allen, L., Rossi, M., & Longobardi, V. (2009) · PubMed · Cited by 10
Structural and functional brain alterations in Cushing’s disease: A narrative review
Liu, Y.-F., Pan, L., & Feng, M. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101033 · Cited by 8
Ehrlich, K., Morbach, C., Reiter, T., Heuschmann, P. U., Hannemann, A., Faßnacht, M., Störk, S., Hahner, S., & Deutschbein, T. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00665-7 · Cited by 7
“Of note, some studies even described suicidal tendencies or suicides in (currently or formerly) affected CS patients [17, 57].”
Glucocorticoid Withdrawal Syndrome
Hochberg, Z. (2004) · The Endocrinologist · doi:10.1097/01.ten.0000127931.93592.fb · Cited by 7
Gillespie, C. F., Szabo, S. T., & Nemeroff, C. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00036-9 · Cited by 7
Keil, M. F., Kang, J. Y., Liu, A., Wiggs, E. A., Merke, D. P., & Stratakis, C. A. (2021) · Clinical Endocrinology · doi:10.1111/cen.14611 · Cited by 6
The relationship between panic disorder and hypertension. A review of literature
Bladowski, M., Mazur, G. J., & Małyszczak, K. (2021) · Psychiatria Polska · doi:10.12740/pp/116570 · Cited by 6
“This is most likely related to the relative cortisol deficiency and the subsequent uncontrolled increase in catecholamine concentration [39].”
BackgroundImproving Quality of Life in Patients with Pituitary Tumours
Crespo, I., Vives, A. S., Resmini, E., Valassi, E., Martínez-Momblán, M.-A., & Webb, S. M. (2014) · US Endocrinology · doi:10.17925/use.2014.10.01.79 · Cited by 9
Neurological Complications of Endocrine Disease
Carvalho, K. S., Grunwald, T., & Luca, F. D. (2016) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2016.12.006 · Cited by 8
A case of acute confusion: Cushing’s syndrome presenting with primary hyperparathyroidism
Irvine, E., Yap, Y. W., Purewal, T., & Irvine, E. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-218694 · Cited by 5
Egalini, F., Caprino, M. P., Gaggero, G., Cappiello, V., Giannelli, J., Giaccherino, R. R., Pagano, L., & Giordano, R. (2021) · Endocrines · doi:10.3390/endocrines2030018 · Cited by 5
Cushing’s syndrome: a systematic review of psychiatric and cognitive symptoms in case studies
Lhul, R. V. D. S., Nunes, K. G., de Almeida, T. S., Czepielewski, M. A., & Czepielewski, L. S. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2026-0029 · Cited by 4
Dimopoulou, C., Geraedts, V. J., Stalla, G. K., & Sievers, C. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006134 · Cited by 5
Cushing’s Disease Presenting with Functional Neurological (Conversion) Disorder
Ashrafzadeh, S., Mariano, M. T., & Syed, S. (2023) · Case Reports in Psychiatry · doi:10.1155/2023/1662271 · Cited by 4
“However, recovery from psychiatric illness can be gradual and may take over 12 months after treatment of CS [10].”
BackgroundGlucocorticoid-Dependent Epigenetic Regulation of Fkbp5
Lee, R. S. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-24493-8_4 · Cited by 4
Genetics of Pituitary Adenomas
Bogusławska, A., Gilis‐Januszewska, A., & Korbonits, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-90475-3_4 · Cited by 6
Brain and eye involvement in McCune-Albright Syndrome: clinical and translational insights
Mascioli, I., Iapadre, G., Ingrosso, D. M. F., Donato, G., Giannini, C., Salpietro, V., Chiarelli, F., & Farello, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1092252 · Cited by 5
“Notably, studies in adult individuals affected with Cushing’s syndrome report a high incidence of neuropsychiatric diseases, most commonly depression and/or major affective disorders, and these complications are usually reversible after treatment (57).”
BackgroundDo glucocorticoids induce addiction in humans?
Giordano, R., Guaraldi, F., Mazzoli, M., & Ghigo, E. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0656-4 · Cited by 4
“withdrawal syndrome [8, 10], since acute stress-induced HPA activation and dopamine release in the mesolimbic system promote behavioral activation toward appropriate stimulus response, while prolonged stress exposure inhibits the mesolimbic dopaminergic system, with failure of coping, and subsequent depressive manifes…”
BackgroundInfluentialStabilisation of the hypothalamic-pituitary-adrenal axis as a treatment modality for mood disorders
Thakore, J. H. (1998) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199803)13:2<77::aid-hup960>3.0.co;2-l · Cited by 4
“In fact, over 24 per cent of patients who had had their hypercortisolism corrected continue to complain of signi®cant psychopathology, including depression, panic disorder and increased frequency of suicidal ideation (Dorn et al., 1997).”
BackgroundMurck, H., Uhr, M., Schaffler, K., & Seibel, K. (2004) · Neuropsychobiology · doi:10.1159/000079103 · Cited by 4
The influence of Rooibos (Aspalathus linearis) on adrenal steroidogenic P450 enzymes
Perold, H. (2009) · SUNScholar (Stellenbosch University) · Cited by 8
Garg, M., & Mittal, M. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_542_20 · Cited by 4
“[5,6] Thus, both structural and functional outcomes of hypercortisolism on the brain have been well documented in CS.”
InfluentialLondoño, F. U., Franco, J. G., Franco, L. F. M., & Tobón, L. A. L. (2005) · IATREIA · doi:10.17533/udea.iatreia.4249 · Cited by 3
The Symptoms of Depression in Endocrine Disorders
Hutto, B. (1999) · CNS Spectrums · doi:10.1017/s109285290001155x · Cited by 3
“However, the recovery may be slow or incomplete.(32) Cushing's disease, like depression, is also more common in women.”
BackgroundImpact of acromegaly and the Cushing's syndrome, a prospect experience
Llanes, L. L., Machado, A. A., Redondo, B. L. F., & Rodríguez, J. H. (2011) · Revista cubana de endocrinología · Cited by 3
Behavioral Medical Epigenetics
Cox, O., & Lee, R. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00008-9 · Cited by 4
Koch, C. A., & Chrousos, G. P. (2003) · doi:10.1007/978-1-59259-390-3_4 · Cited by 3
Self-citationCircadian Clocks, Stress, and Psychiatric Disorders
Kling, C., & Landgraf, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813156-5.00008-x · Cited by 3
Are There Connections between the Neuroendocrine and Dopamine Systems in Bipolar Disorder?
Trouillas, J., Claustrat, B., Henry, E., Lemius, J., Alafuzoff, I. I., & Nataf, S. (2025) · Neuroendocrinology · doi:10.1159/000547042 · Cited by 2
“Nevertheless, it should be noticed that in some patients, notably children, depression and irritability may remain unchanged after correction of hypercortisolism [53, 54].”
DYNAMICS OF PSYCHIATRIC SYMPTOMS IN CUSHING’S SYNDROME
Telbizova, T., Aleksandrov, I., & Arnaoudova, M. (2020) · Journal of IMAB - Annual Proceeding (Scientific Papers) · doi:10.5272/jimab.2020264.3443 · Cited by 2
Lee, J., Li, C. H., Liu, C. J., Shiroishi, M. S., Carmichael, J. D., Zada, G., & Patel, V. N. (2022) · Surgical Neurology International · doi:10.25259/sni_787_2021 · Cited by 3
Sulu, C., KAYNAK, G. K., KÖSKÜN, T., Koca, O., Icli, T. B., Kavla, Y., Özkaya, H. M., Turan, Ş., Eskin, M., & Kadıoğlu, P. (2022) · Pituitary · doi:10.1007/s11102-022-01275-3 · Cited by 2
Metadata
- Authors
- Dorn, L. D., Burgess, E. S., Friedman, T. C., Dubbert, B., Gold, P. W., & Chrousos, G. P.
- Affiliations
- University of Pittsburgh (US)
- Brown University (US)
- Cedars-Sinai Medical Center (US)
- the Departments of Behavioral Pediatrics (B.D.), Bethesda, Maryland 20892;
- National Institute of Mental Health (US)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- Corresponding author
- Dorn, Lorah D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-03-01
- Volume
- 82
- Issue
- 3
- Pages
- 912-919
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2022989916
- Cited by
- 260
- References
- 31
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 10 · 2023: 10 · 2022: 8 · 2021: 16 · 2020: 11 · 2019: 8 · 2018: 15 · 2017: 11 · 2016: 10 · 2015: 16 · 2014: 12 · 2013: 20 · 2012: 14
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, hypercortisolism, psychopathology, major affective disorders, hypothalamic-pituitary-adrenal axis, ACTH stimulation test, morning cortisol, suicidal ideation, panic attacks, longitudinal course
- MeSH terms
- Adrenalectomy, Adult, Mental Disorders, Cushing Syndrome, Female, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Longitudinal Studies, Male, Medical Records, Middle Aged, Pituitary-Adrenal System, Postoperative Complications, Prospective Studies, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.